Clinical Trial Update: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update for CLBR001 and SWI019 in relapsed/refractory B-cell malignancies has completed enrollment in a study targeting multiple B-cell lymphoma su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• CLBR001
• SWI019

Snippet

Sponsor: Calibr, a division of Scripps Research | Conditions: Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Status: COMPLETED